Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.

Launched by GENE SOLUTIONS · Oct 16, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a blood test called ctDNA, which can help doctors understand how breast cancer is responding to treatment. The study aims to see how often ctDNA is found in the blood before, during, and after neoadjuvant chemotherapy (a treatment given before surgery to shrink tumors) in women with specific types of breast cancer, including HER2-positive and triple-negative breast cancer. Researchers will also compare the ctDNA results with MRI imaging to see how well the treatment is working and predict outcomes for patients.

To participate in this study, women must be 18 years or older and diagnosed with stage II or III HER2-positive or triple-negative breast cancer that requires neoadjuvant chemotherapy. Participants will provide blood samples and may undergo MRI scans while they receive treatment. The trial is currently recruiting participants, and those who join will help researchers learn more about the effectiveness of ctDNA and imaging in managing breast cancer care.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female,18 years old and older,
• • Are diagnosed with stage II-III HER2+/Triple Negative breast cancer and indicated for neoadjuvant chemotherapy,
• • FFPE sample is available at the time of diagnosis and operation,
• • Are voluntary to participate in the study.
• Exclusion Criteria:
• • Recurrent breast cancer,
• • Other cancer metastasis to the breast,
• • Have been or are being treated for cancer,
• • Patients did not agree to participate in the studies.